References of "Luxen, André"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCircadian dynamics in measures of cortical excitation and inhibition balance
Chellappa, Sarah; Gaggioni, Giulia ULiege; LY, Julien ULiege et al

in Scientific Reports (2016), 6:33661

Detailed reference viewed: 40 (13 ULiège)
Full Text
Peer Reviewed
See detailBiodistribution of Novel 68Ga-Radiolabelled HER2 Aptamers in Mice
Gijs, Marlies; Becker, Guillaume ULiege; Plenevaux, Alain ULiege et al

in Journal of Nuclear Medicine and Radiation Therapy (2016), 7(5),

Background: Two novel HER2 aptamers were recently selected with great potential for the in vitro diagnosis of HER2-positive cancer. The goal of this study was to examine the in vivo diagnostic potential ... [more ▼]

Background: Two novel HER2 aptamers were recently selected with great potential for the in vitro diagnosis of HER2-positive cancer. The goal of this study was to examine the in vivo diagnostic potential of these HER2 aptamers. Methods: Both HER2 aptamers were radiolabelled with 68Ga, injected in mice bearing a HER2-positive and HER2-negative tumour and evaluated by PET/MRI. Results: Ex vivo bio distribution analysis revealed high uptake in the blood, tissues and organs, except the brain. Interestingly, this high uptake was explained by the slow blood clearance due to non-specific aptamer binding to blood proteins. We observed accumulation of radioactivity in both tumours in time. Although higher uptake in the HER2-positive tumour compared to the HER2-negative tumour was observed, this was accompanied with more necrosis in the HER2-negative tumour, which was observed by 18FDG PET/CT. Conclusion: This work presents a first step towards the development of 68Ga-labelled aptamers for molecular cancer imaging. [less ▲]

Detailed reference viewed: 72 (15 ULiège)
Full Text
Peer Reviewed
See detailLocal modulation of human brain responses by circadian rhythmicity and sleep debt
Muto, Vincenzo ULiege; Jaspar, Mathieu ULiege; Meyer, Christelle et al

in Science (2016), 351(6300),

Detailed reference viewed: 105 (37 ULiège)
Full Text
Peer Reviewed
See detailIn vivo quantification of dopaminergic terminals loss in Parkinson’s Disease rat model: comparison between [18F]FMT and [18F]FDOPA.
Becker, Guillaume ULiege; Bahri, Mohamed Ali ULiege; Michel, Anne et al

in Molecular Imaging & Biology (2016, July), 18(S1), 1744

Objectives: Rat models of Parkinson’s disease (PD), such as unilaterally lesioned rats with 6-hydroxydopamine (6-OHDA), are useful to evaluate novel antiparkinsonian therapies. MicroPET imaging, using L-3 ... [more ▼]

Objectives: Rat models of Parkinson’s disease (PD), such as unilaterally lesioned rats with 6-hydroxydopamine (6-OHDA), are useful to evaluate novel antiparkinsonian therapies. MicroPET imaging, using L-3,4-dihydroxy-6-[18F]-fluoro-phenylalanine ([18F]FDOPA) allows longitudinal evaluations of DA terminals loss. However, chemical structure of [18F]FDOPA leads to suboptimal PET imaging. 18F-fluoro-m-tyrosine ([18F]FMT) is an effective PET tracer to evaluate DA terminals integrity and L-aromatic amino acid decarboxylase (AAAD) metabolic pathway. So far, there are no available quantitative PET studies comparing the two methods in hemiparkinsonian rats. In this study, we compare imaging data provided by [18F]FMT PET and [18F]FDOPA PET in 6-OHDA-lesioned rats. Methods: 10 µg of 6-OHDA were injected into the right medial forebrain bundle (MFB) of male Sprague-Dawley rats (n=8). As control, sham-treated rats (n=8) were injected with vehicle only but otherwise treated identically. Striatal DA presynaptic activity was assessed by dynamic PET with both [18F]FMT and [18F]FDOPA. Structural T2-weighted brain images were acquired on a 9.4T MRI and were used for co-registration. After normalization on a MRI template, kinetic analysis was performed by “Patlak Reference” model, using PMOD software. Six days after the last PET scan, rats were sacrificed, and striatum were rapidly removed for striatal DA and metabolites quantification. Results: Striatal accumulation was observed for both tracers. However, while the administration of [18F]FDOPA required two peripheral inhibitors (benserazide and entacapone), only benserazide is needed with [18F]FMT. As consequence of the 6-OHDA-lesion, significant decrease of both [18F]FMT and [18F]DOPA accumulation was recorded in the striatum ipsilateral to the lesion. Lesioned rats had dramatically reduced uptake constant Ki in the ipsilateral striatum compared to the contralateral striatum (p<0.001 for [18F]FMT and p<0.05 for [18F]DOPA) and to the ipsilateral striatum of sham-treated rats (p<0.001 for both tracers). The DA content in the ipsilateral striatum was significantly lower (p<0.001) than in the contralateral striatum in the 6-OHDA-injected group, whereas such difference was not measured with the sham group. This indicate that [18F]FMT PET is as effective as [18F]DOPA PET to quantify loss of DA presynaptic function in unilaterally 6-OHDA lesioned rats. Conclusions: Our results are in agreement with data reporting correlation between these two tracers in a Non-human primate model of PD. The sensitivity of the data quantification obtained in this study, confirms the interest to pursue longitudinal investigations with [18F]FMT to monitor dopaminergic dysfunction in a more progressive preclinical model of PD. [less ▲]

Detailed reference viewed: 75 (10 ULiège)
Full Text
Peer Reviewed
See detailFully automated radiosynthesis of N1-[18F]fluoroethyl-tryptophan and study of its biological activity as a new potential substrate for indoleamine 2,3-dioxygenase PET imaging
Henrottin, Jean ULiege; Lemaire, Christian ULiege; Egrise, Dominique et al

in Nuclear Medicine & Biology (2016), 43(6), 379-389

Introduction: Indoleamine 2,3-dioxygenase (IDO) catalyzes the initial step in the catabolism of L-tryptophan along the kynurenine pathway and exerts immunosuppressive properties in inflammatory and tumor ... [more ▼]

Introduction: Indoleamine 2,3-dioxygenase (IDO) catalyzes the initial step in the catabolism of L-tryptophan along the kynurenine pathway and exerts immunosuppressive properties in inflammatory and tumor tissues by blocking locally T-lymphocyte proliferation. Recently, 1-(2-[19F]fluoroethyl)-DL-tryptophan (1-[19F]FE-DL-Trp) was reported as a good and specific substrate of this enzyme. Herein, the radiosynthesis of its radioactive isotopomer (1-[18F]FE-DL-Trp, DL-[18F]5) is presented along with in vitro enzymatic and cellular uptake studies. Methods: The one-pot n.c.a. radiosynthesis of this novel potential PET imaging tracer, including HPLC purification and formulation, has been fully automated on a FASTlabTM synthesizer. Chiral separation of both isomers and their formulation were implemented on a second cassette. In vitro enzymatic and cellular uptake studies were then conducted with the D-, L- and DL-radiotracers. Results: The radiolabeling of the tosylate precursor was performed in DMF (in 5 min; RCY: 57% (d.c.), n=3). After hydrolysis, HPLC purification and formulation, DL-[18F]5 was obtained with a global radiochemical yield of 18±3% (not decay corrected, n=7, in 80 min) and a specific activity of 600±180 GBq/µmol (n=5). The subsequent separation of L- and D-enantiomers was performed by chiral HPLC and both were obtained after formulation with a RCY (d.c.) of 6.1% and 5.8%, respectively. In vitro enzymatic assays reveal that L-[18F]5 is a better substrate than D-[18F]5 for human IDO. In vitro cellular assays show an IDO-specific uptake of the racemate varying from 30% to 50% of that of L-[18F]5, and a negligible uptake of D-[18F]5. Conclusion: In vitro studies show that L-[18F]5 is a good and specific substrate of hIDO, while presenting a very low efflux. These results confirm that L-[18F]5 could be a very useful PET radiotracer for IDO expressing cells in cancer imaging. [less ▲]

Detailed reference viewed: 50 (14 ULiège)
Peer Reviewed
See detailSeasonal variation in human COGNITIVE brain responses
Meyer, Christelle; Muto, Vincenzo ULiege; Jaspar, Mathieu ULiege et al

Poster (2016, June)

Detailed reference viewed: 27 (4 ULiège)
Full Text
Peer Reviewed
See detailDevelopment of solid-supported methodology for the preparation of peptidoglycan fragments containing (2S,6R)-diaminopimelic acid
Simon, Justine ULiege; Lamborelle, Nicolas ULiege; Zervosen, Astrid et al

in Tetrahedron Letters (2016)

Herein, we describe the development of an efficient solid-supported methodology for the stereoselective synthesis of two peptides containing (2S,6R)-diaminopimelic acid, (S)-Ala-γ-(R)-Glu-(2S,6R)-A2pm-(R ... [more ▼]

Herein, we describe the development of an efficient solid-supported methodology for the stereoselective synthesis of two peptides containing (2S,6R)-diaminopimelic acid, (S)-Ala-γ-(R)-Glu-(2S,6R)-A2pm-(R)-Ala 1 and γ-(R)-Glu-(2S,6R)-A2pm 2. The platform consists of a Wang resin anchored by an amino acid chain including allylglycine. By olefin cross metathesis with vinylglycine, unsaturated protected (2S,6R)-A2pm was fixed on solid support. Peptides were achieved by cleavage of cross metathesis products from resin, followed by reduction of double bonds along removing of protecting groups. Furthermore, this efficient solid phase approach will lead to peptide and muropeptide libraries. [less ▲]

Detailed reference viewed: 52 (22 ULiège)
Full Text
Peer Reviewed
See detailEVALUATION OF SV2Alox/Cre TRANSGENIC MICE USING [18F]UCB-H IN VITRO AUTORADIOGRAPHY
Serrano Navacerrada, Maria Elisa ULiege; Becker, Guillaume ULiege; MENTEN, Catherine ULiege et al

Poster (2016, March 09)

Introduction Epilepsy is one of the commonest neurological disorders [1]. Antiepileptic drugs mainly target the SV2A protein [2] but its actual role is still largely unknown. [18F]UCB-H was developed to ... [more ▼]

Introduction Epilepsy is one of the commonest neurological disorders [1]. Antiepileptic drugs mainly target the SV2A protein [2] but its actual role is still largely unknown. [18F]UCB-H was developed to study in vivo SV2A brain proteins [3, 4]. The present pilot study was undertaken to evaluate for the first time in vivo in rats SV2A expression in the Kaïnic Acid (KA) epilepsy model [5]. Although this model is well studied in mice, few reports were devoted to rats. Imaging-wise, rats are very interesting thanks to a bigger brain size (reduction of the partial volume effect). Methods Three male Sprague-Dawley were used, one injected with saline and two with multiple KA injections (3 x 5mg/kg) [6]. 75 days later, when spontaneous seizures started to appear, microPET (Focus 120 ) was performed under isoflurane anesthesia (2.5-3 % in air) for 1 hour with [18F]UCB-H (41 ± 5 MBq IV tail vein) followed by MRI (9.4T Agilent, anatomical T2). Coregistration was done with PMOD 3.6 software. Data were expressed as SUV and areas under the curve were calculated for the different regions. Results [18F]UCB-H microPET images showed an important reduction (20-30%) for SV2A after KA injections mainly localized in amygdala, hippocampus, lateral parietal association cortex and cingulate cortex. The rest of the brain was globally unchanged. MRI revealed atrophy and inflammation in amygdala and hippocampus. Conclusions These preliminary results obtained in KA treated rats showed that [18F]UCB-H was able to detect important modifications for SV2A in relevant regions for epilepsy and appears as a valuable tool to follow in vivo SV2A through longitudinal studies. KA model in rats deserves for further development and validation as a tool for the study of epilepsy. [less ▲]

Detailed reference viewed: 35 (8 ULiège)
Full Text
Peer Reviewed
See detailIn vivo evaluation of [18F]UCB-H binding at SV2A protein, through a new and efficient radiosynthesis of [18F]UCB-H.
Becker, Guillaume ULiege; Warnier, C; Serrano Navacerrada, Maria Elisa ULiege et al

Poster (2016, March 08)

Background: [18F]UCB-H is a validated radiotracer with a high affinity for the synaptic vesicle glycoprotein 2A (SV2A), known as the binding site of the antiepileptic drug levetiracetam [1, 2]. The major ... [more ▼]

Background: [18F]UCB-H is a validated radiotracer with a high affinity for the synaptic vesicle glycoprotein 2A (SV2A), known as the binding site of the antiepileptic drug levetiracetam [1, 2]. The major drawback of [18F]UCB-H was a long, multi-step radiosynthesis with limited yield of radiotracer [3]. We provide here in vivo evaluation of a new efficient single-step radiosynthesis of [18F]UCB-H, that allows us to highlight the role of the enantio-selectivity while targeting SV2A. Then, we synthetized and radiolabeled the major metabolite, namely [18F]UCB-H-N-oxyde, and investigated its impact on rat brain PET images. Methods: [18F]UCB-H was produced with a simple, one-step production strategy which consisted in radiolabeling an enantiomerically pure (S- or R-) N-heteroaryliodonium precursor [4]. 5 Sprague-Dawley (SD) rats underwent 1 dynamic PET scan (60 minutes) with each enantiomer and a third one with the racemic mixture. We used a population-based input function (PBIF) to quantify [18F]UCB-H binding with Logan graphical analysis. [18F]UCB-H-N-oxyde was produced by a direct oxidation with a large excess of pure m-CPBA in Et2O. 5 SD rats underwent 1 dynamic PET scan (60 minutes) with this radiosynthetic [18F]UCB-H-N-oxyde. Results: The radiosynthesis lasted 60 min and afforded a 34 ± 2% radiochemical yield, non-corrected for decay, with a high specific activity (820 ± 180 GBq/µmol). Time activity curves showed higher values for the [18F]UCB-H compared to both the S-[18F]UCB-H and the racemic. Distribution volume (Vt) of the [18F]UCB-H, measured with the PBIF were consistent with previous study [2]. Analysis of [18F]UCB-H-N-oxyde PET images confirmed the absence of Blood-Brain-Barrier crossing. Conclusions: This new [18F]UCB-H radiosynthesis allows us to reach high specific activities. In vivo results are consistent with previous work and emphasize the need of high enantiomeric purity to reach accurate quantitative values of radiotracer binding. The use of a PBIF to quantify [18F]UCB-H binding in the rat brain is reliable and afford longitudinal study. At the end, our study demonstrated that [18F]UCB-H fulfils an important criterion for PET radiopharmaceuticals with the lack of troublesome brain radiometabolites. [less ▲]

Detailed reference viewed: 23 (3 ULiège)
Full Text
Peer Reviewed
See detailIn vivo quantification of dopaminergic terminals loss in Parkinson’s Disease rat with AAV-induced overexpression of alpha-synuclein: a [18F]FMT microPET study.
Becker, Guillaume ULiege; Bahri, Mohamed Ali ULiege; Michel, Anne et al

Poster (2016, March 08)

Objectives: Rat models of Parkinson’s disease (PD), such as progressive neurodegeneration induced by adeno-associated virus (AAV)-mediated over-expression of human -synuclein (A53T) in midbrain dopamine ... [more ▼]

Objectives: Rat models of Parkinson’s disease (PD), such as progressive neurodegeneration induced by adeno-associated virus (AAV)-mediated over-expression of human -synuclein (A53T) in midbrain dopamine neurons, are useful to evaluate novel antiparkinsonian therapies [1]. In vivo quantitative imaging of dopamine neurotransmission allows longitudinal evaluation of such PD’s rat model [2]. In this study, we investigate DA presynaptic function, with [18F]FMT PET (radiotracer of the L-aromatic amino acid decarboxylase enzyme), in the AAV A53T PD’s rat model, and correlate the results with behavioral measurements. Methods: All animals were injected with 2 µL A53T -synuclein (n=6) or GFP (n=2) AAV2/9 in the right substantia nigra. Striatal DA presynaptic activity was assessed by dynamic PET with [18F]FMT [3] at 18 weeks post-lesion. Kinetic analysis was performed by “Patlak Reference” model, using PMOD software. Rats were monitored for motor behavior and assessed before the lesion, and at 4, 12 and 18 weeks post-lesion. Results: As consequence of AAV-mediated A53T overexpression, significant decrease of [18F]FMT accumulation was recorded in the striatum ipsilateral to the lesion. Lesioned rats had dramatically reduced uptake constant Ki in the ipsilateral striatum compared to the contralateral striatum (p<0.001 for [18F]FMT) and to the ipsilateral striatum of sham-treated rats (p<0.001). Significant deficit in stepping adjustment was observed with the contralateral forepaw at 4, 12 and 18 weeks. Significant reduction of the time spent on the rotarod was also measured at 12 and 18 weeks. Conclusions: Our results report good correlations between [18F]FMT PET outcomes and behavioral results. The sensitivity of the data quantification obtained in this study, confirms the interest to pursue longitudinal investigations with [18F]FMT to monitor dopaminergic dysfunction in this progressive preclinical model of PD. [less ▲]

Detailed reference viewed: 32 (3 ULiège)
Full Text
Peer Reviewed
See detailSeasonality in human cognitive brain responses
Meyer, Christelle ULiege; Muto, Vincenzo ULiege; Jaspar, Mathieu ULiege et al

in Proceedings of the National Academy of Sciences of the United States of America (2016)

Detailed reference viewed: 137 (19 ULiège)
Full Text
Peer Reviewed
See detailGallium-68-labelled NOTA-oligonucleotides: An optimized method for their preparation
Gijs, Marlies; Dammicco, Sylvestre ULiege; Warnier, Corentin ULiege et al

in Journal of Labelled Compounds & Radiopharmaceuticals (2016)

One of the most essential aspects to the success of radiopharmaceuticals is an easy and reliable radiolabelling protocol to obtain pure and stable products. In this study, we optimized the bioconjugation ... [more ▼]

One of the most essential aspects to the success of radiopharmaceuticals is an easy and reliable radiolabelling protocol to obtain pure and stable products. In this study, we optimized the bioconjugation and gallium-68 ((68) Ga) radiolabelling conditions for a single-stranded 40-mer DNA oligonucleotide, in order to obtain highly pure and stable radiolabelled oligonucleotides. Quantitative bioconjugation was obtained for a disulfide-functionalized oligonucleotide conjugated to the macrocylic bifunctional chelator MMA-NOTA (maleimido-mono-amide (1,4,7-triazanonane-1,4,7-triyl)triacetic acid). Next, this NOTA-oligonucleotide bioconjugate was radiolabelled at room temperature with purified and pre-concentrated (68) Ga with quantitative levels of radioactive incorporation and high radiochemical and chemical purity. In addition, high chelate stability was observed in physiological-like conditions (37 °C, PBS and serum), in the presence of a transchelator (EDTA) and transferrin. A specific activity of 51.1 MBq/nmol was reached using a 1470-fold molar excess bioconjugate over (68) Ga. This study presents a fast, straightforward and reliable protocol for the preparation of (68) Ga-radiolabelled DNA oligonucleotides under mild reaction conditions and without the use of organic solvents. The methodology herein developed will be applied to the preparation of oligonucleotidic sequences (aptamers) targeting the human epidermal growth factor receptor 2 (HER2) for cancer imaging. [less ▲]

Detailed reference viewed: 23 (6 ULiège)
Full Text
Peer Reviewed
See detailAptamers as radiopharmaceuticals for nuclear imaging and therapy
Gijs, M.; Aerts, A.; Impens, N. et al

in Nuclear Medicine & Biology (2016), 43(4), 253-271

Today, radiopharmaceuticals belong to the standard instrumentation of nuclear medicine, both in the context of diagnosis and therapy. The majority of radiopharmaceuticals consist of targeting biomolecules ... [more ▼]

Today, radiopharmaceuticals belong to the standard instrumentation of nuclear medicine, both in the context of diagnosis and therapy. The majority of radiopharmaceuticals consist of targeting biomolecules which are designed to interact with a disease-related molecular target. A plethora of targeting biomolecules of radiopharmaceuticals exists, including antibodies, antibody fragments, proteins, peptides and nucleic acids. Nucleic acids have some significant advantages relative to proteinaceous biomolecules in terms of size, production, modifications, possible targets and immunogenicity. In particular, aptamers (non-coding, synthetic, single-stranded DNA or RNA oligonucleotides) are of interest because they can bind a molecular target with high affinity and specificity. At present, few aptamers have been investigated preclinically for imaging and therapeutic applications. In this review, we describe the use of aptamers as targeting biomolecules of radiopharmaceuticals. We also discuss the chemical modifications which are needed to turn aptamers into valuable (radio-)pharmaceuticals, as well as the different radiolabeling strategies that can be used to radiolabel oligonucleotides and, in particular, aptamers. © 2015 Elsevier Inc. [less ▲]

Detailed reference viewed: 12 (0 ULiège)
Full Text
Peer Reviewed
See detailImproved aptamers for the diagnosis and potential treatment of HER2-positive cancer
Gijs, M.; Penner, G.; Blackler, G. B. et al

in Pharmaceuticals (2016), 9(2),

Aptamers provide a potential source of alternative targeting molecules for existing antibody diagnostics and therapeutics. In this work, we selected novel DNA aptamers targeting the HER2 receptor by an ... [more ▼]

Aptamers provide a potential source of alternative targeting molecules for existing antibody diagnostics and therapeutics. In this work, we selected novel DNA aptamers targeting the HER2 receptor by an adherent whole-cell SELEX approach. Individual aptamers were identified by next generation sequencing and bioinformatics analysis. Two aptamers, HeA2_1 and HeA2_3, were shown to bind the HER2 protein with affinities in the nanomolar range. In addition, both aptamers were able to bind with high specificity to HER2-overexpressing cells and HER2-positive tumor tissue samples. Furthermore, we demonstrated that aptamer HeA2_3 is being internalized into cancer cells and has an inhibitory effect on cancer cell growth and viability. In the end, we selected novel DNA aptamers with great potential for the diagnosis and possible treatment of HER2-positive cancer. © 2016 by the authors; licensee MDPI, Basel, Switzerland. [less ▲]

Detailed reference viewed: 17 (0 ULiège)
Full Text
Peer Reviewed
See detailCircadian and homeostatic sleep pressure modulate fMRI correlates of vigilant attention
Muto, Vincenzo ULiege; Jaspar, Mathieu ULiege; Meyer, C et al

in Journal of Sleep Research (2016), 25(s1),

Detailed reference viewed: 49 (4 ULiège)
Full Text
Peer Reviewed
See detailCircadian regulation of human cortical excitability
LY, Julien ULiege; Gaggioni, Giulia ULiege; Chellappa, Sarah et al

in Nature Communications (2016)

Detailed reference viewed: 45 (6 ULiège)
Full Text
Peer Reviewed
See detailNeural correlates of successful memory retrieval in aging: Do executive functioning and task difficulty matter?
Angel, Lucie; Bastin, Christine ULiege; Genon, Sarah ULiege et al

in Brain Research (2016), 1631

Detailed reference viewed: 39 (6 ULiège)
Full Text
Peer Reviewed
See detailMonte Carlo simulations of the dose from imaging with GE eXplore 120 micro-CT using gate.
Bretin, Florian; Bahri, Mohamed Ali ULiege; Luxen, André ULiege et al

in Medical Physics (2015), 42(10), 5711-5719

Purpose: Small animals are increasingly used as translational models in preclinical imaging studies, during which the subjects can be exposed to large amounts of radiation. While the radiation levels are ... [more ▼]

Purpose: Small animals are increasingly used as translational models in preclinical imaging studies, during which the subjects can be exposed to large amounts of radiation. While the radiation levels are generally sublethal, studies have shown that low-level radiation can change physiological parameters in mice. In order to rule out any influence of radiation on the outcome of such experiments, or resulting deterministic effects in the subjects, the levels of radiation involved need to be addressed. The aim of this study was to investigate the radiation dose delivered by the GE eXplore 120 microCT non-invasively using Monte Carlo simulations in GATE and to compare results to previously obtained experimental values. Methods: Tungsten X-ray spectra were simulated at 70, 80, and 97 kVp using an analytical tool and their half-value layers were simulated for spectra validation against experimentally measured values of the physical X-ray tube. A Monte Carlo model of the microCT system was set up and four protocols that are regularly applied to live animal scanning were implemented. The computed tomography dose index (CTDI) inside a PMMA phantom was derived and multiple field of view acquisitions were simulated using the PMMA phantom, a representative mouse and rat. Results: Simulated half-value layers agreed with experimentally obtained results within a 7% error window. The CTDI ranged from 20 to 56 mGy and closely matched experimental values. Derived organ doses in mice reached 459 mGy in bones and up to 200 mGy in soft tissue organs using the highest energy protocol. Dose levels in rats were lower due to the increased mass of the animal compared to mice. The uncertainty of all dose simulations was below 14%. Conclusions: Monte Carlo simulations proved a valuable tool to investigate the 3D dose distribution in animals from microCT. Small animals, especially mice (due to their small volume), receive large amounts of radiation from the GE eXplore 120 microCT, which might alter physiological parameters in a longitudinal study setup. [less ▲]

Detailed reference viewed: 34 (4 ULiège)
See detailSeasonality in human cognitive brain responses.
Meyer, Christelle ULiege; Muto, Vincenzo ULiege; Jaspar, Mathieu ULiege et al

Poster (2015, September 04)

Detailed reference viewed: 172 (11 ULiège)
Full Text
See detailEVALUATION OF SV2Alox/Cre TRANSGENIC MOUSE USING [18F]UCB-H IN IN VITRO AUTORADIOGRAPHY
Serrano Navacerrada, Maria Elisa ULiege; Becker, Guillaume ULiege; MENTEN, Catherine ULiege et al

Poster (2015, September 04)

Background: SV2A is the most studied isoform of the Synaptic Vesicle 2 proteins, which are involved in the synaptic vesicle trafficking. Interestingly, the SV2A has been identify as the binding site for ... [more ▼]

Background: SV2A is the most studied isoform of the Synaptic Vesicle 2 proteins, which are involved in the synaptic vesicle trafficking. Interestingly, the SV2A has been identify as the binding site for the antiepileptic drug levetiracetam, showing a close relation between the epilepsy, the dysregulation of the SV2A levels and the response to antiepileptic medications. SV2A floxed-mice were developed using a cre-lox technique, leading to a strong decrease of SV2A expression in the CA3 field of the hippocampus. We aim here to validate this model using [18F]UCB-H, a novel PET imaging radiotracer with a nanomolar affinity for human SV2A. Methods: In vitro autoradiography were performed on SV2Alox/Cre+ transgenic mouse brain slices. SV2Alox/Cre- mouse was used as control. To obtain a structural reference, brain slices underwent eosin-haematoxylin staining. Images of both procedures were coregistered using π-PMOD software. Regions of interest (Dentate Gyrus, CA1, CA2 and CA3) were drawn according to a stereotaxic atlas of the mouse brain. Results: Analyses showed significant differences in radiotracer binding (p<0.001) between SV2Alox/Cre+ mouse and SV2Alox/Cre- mouse highlighting an important reduction for the labelling density in Ammon's horn, particularly in CA1, compared to Dentate Gyrus where the diminution was less marked. Conclusions: Here, we used the radiotracer [18F]UCB-H to probe the decreased expression of SV2A protein in the hippocampus of SV2Alox/Cre+ mouse versus SV2Alox/Cre- control mouse. Our results contribute to the validation of the model, and encourage us to proceed with further longitudinal and behavioural studies. [less ▲]

Detailed reference viewed: 107 (47 ULiège)